drugset / Trial / NCT04523246

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246

RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19. We hypothesize that: H1: Shingrix vaccination will elevate acute and trained immunity H2: For 6 months following the first injection, increased levels of acute and trained immunity is associated with less disease, including fewer hospitalizations and deaths associated with flu, pneumonia, and COVID-19.

Timeline

Start
2020-09-01
Primary completion
2021-12-30
Completion
2023-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E Vaccine 0.5 ml Intramuscular

Indications